Organizations that thrive typically all have one thing in common: They understand what contributes, and detracts, from their bottom line. But mastering that task in a world of hidden government pricing is becoming a tightrope walk. That’s because government pricing programs can disproportionately impact sales channels—and paint a vastly different picture of a company’s financial status when comparing gross and net incomes.
Small biotech companies are frequently unaware of the impact government pricing channels will have on their developing financial models for new products. Government-regulated payers—such as Medicaid, Medicare, VA, and DOD—often leave financial ambiguity in their wake, as smart, competent, capable companies can’t keep up with the changing rules, regulations and risks inherent in government pricing. They need a guide.
Join Jason Hardaway, Managing Partner at CiiTA LLC, as he discusses government-mandated price controls, such as Medicaid, 340B, and VA—and the hidden impacts of each of these controls on your financial models. You’ll receive a roadmap on how to navigate their nuances and how to avoid their potentially devastating pitfalls. This knowledge, and an understanding of these channels pre-launch, will protect revenue and keep your investors happy.